Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at firstname.lastname@example.org
Kato Unpacks Symptom Management With Nivolumab Combinations in Frontline ESCCJune 13th 2022
Ken Kato, MD, PhD, a medical oncologist at the National Cancer Center of Tokyo, and investigator in the pivotal CheckMate 648 study, underscores relevant safety data updates from the trial and important symptom management considerations with the FDA-approved combinations.
Nurse Takeaways: How to Improve a Patient’s Experience With Sotorasib and Optimize NSCLC TreatmentMay 26th 2022
Oncology nurses present their experiences treating patients with sotorasib in the phase 1/2 CodeBreaK 100 trial and optimal symptom management strategies to improve patient outcomes with the drug.
Patients With Metastatic Urothelial Carcinoma Achieve Superior Survival After Experiencing irAEs With PembrolizumabMay 17th 2022
In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.
Vitamin C Increases Chemotherapy Responses in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder CancerMay 16th 2022
Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c.